What is the deciding factor in a clinician’s choice of drug?
Efficacy of pembrolizumab treatment in mucosal melanoma
Biosimilars are alternatives for original antibodies
The importance of biomarkers to optimize treatment with immunotherapy for melanoma
Prevention and treatment of chemotherapy-induced nausea and vomiting